간질환 진단 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the liver disease diagnostics market size in 2026 is estimated at USD 40.55 billion, growing from 2025 value of USD 37.97 billion with 2031 projections showing USD 56.27 billion, growing at 6.79% CAGR over 2026-2031.

This report is Segmented by Diagnosis Technique (Imaging [Ultrasound and More], Liver Fuction Test, Liver Biopsy and More), Disease Type (NAFLD/MASLD, Viral Hepatitis and More), Technology Platform (Clinical Chemistry, Immunoassay and More) End User (Hospitals, Independent Clinical Laboratoriess, and More), and Geography (North America and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Liver Disease Diagnostics Market Trends and Insights

Growing Prevalence of Liver Diseases Worldwide

Rising MASLD incidence now touches roughly 30% of adults, driven by sedentary lifestyles, calorie-dense diets, and ageing demographics that push metabolic dysfunction to the forefront of hepatology practice.Asia-Pacific bears the world's heaviest chronic Hepatitis B burden, creating sustained surveillance demand even as vaccination programs mature. Epidemiological models in Spain predict MASLD diagnoses doubling by 2030, challenging laboratory capacity and prompting policymakers to subsidize high-throughput non-invasive tests. As patient volumes swell, providers swap liver biopsy for elastography and serum panels that can be repeated frequently without safety concerns. The long-term nature of metabolic disease means each newly diagnosed individual represents a recurring revenue stream for diagnostic vendors throughout disease progression.

Rising Alcohol Consumption & Metabolic Risk Factors

Europe's alcohol-attributable liver morbidity overlaps increasingly with obesity and insulin resistance, making etiology assignment difficult when standard liver enzymes cannot disentangle multifactorial injury. Economic modeling by the European Association for the Study of the Liver shows that instituting a EUR 1 minimum unit price could prevent more than 19,000 severe liver outcomes by 2030, spotlighting diagnostics as a critical companion to policy. Multi-analyte panels that quantify fibrosis, steatosis, and inflammatory markers in one run allow clinicians to stratify complex cases quickly. AI algorithms further integrate behavioral data-such as alcohol purchase records-with laboratory inputs, enabling earlier intervention and supporting value-based reimbursement frameworks.

High Cost of Comprehensive Diagnostic Work-Ups

Full hepatic work-ups that bundle imaging, serum biomarkers, and histology can top USD 1,200, a prohibitive sum in low-resource settings where out-of-pocket spending predominates. The 2025 Clinical Laboratory Fee Schedule curbs Medicare payments on select assays, squeezing provider margins and slowing menu expansion. Cost-effectiveness research shows that MASLD screening by FIB-4 algorithms exceeds standard willingness-to-pay thresholds, deterring widespread adoption until device prices or reimbursement improve. Vendors respond by bundling tests into subscription models linked to clinical outcome guarantees, but uptake remains limited where health-system budgets are tight.

Other drivers and restraints analyzed in the detailed report include:

1. Uptake of Non-Invasive Imaging
2. Government Initiatives for Population Screening for Liver Diseases
3. Limited Reimbursement for Novel Biomarker Panels

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Imaging tests accounted for 43.92% of liver disease diagnostics market size in 2025, with ultrasound retaining the widest installed base thanks to its affordability and operator familiarity. Yet elastography devices post an 8.06% CAGR as clinicians embrace quantitative fibrosis staging during routine outpatient visits. Radiology suites increasingly pair B-mode imaging with real-time shear-wave metrics, eliminating the scheduling delays associated with separate exams. MRI-elastography captures niche demand for precise staging in transplant candidates, whereas CT and PET-CT support oncologic assessment when hepatocellular carcinoma is suspected. Molecular techniques slot in as adjuncts, offering viral genotyping and cancer mutation profiling from a single blood draw. Over the forecast horizon, integration rather than substitution defines competitive positioning: vendors embedding elastography probes into standard ultrasound consoles win procurement committees seeking versatile systems. Enhanced sensitivity to steatosis and inflammation in next-generation contrast-enhanced ultrasound further erodes biopsy reliance, driving a steady migration of diagnostic workload to ambulatory care.

The shift to patient-friendly tests dovetails with payers' focus on cost containment. Point-of-care elastography shortens diagnostic cycles, cutting ancillary costs such as pathology processing and post-biopsy observation. Evidence from multicenter studies demonstrates that shear-wave thresholds of 7 kPa distinguish significant fibrosis with 100% sensitivity, making routine surveillance feasible in primary care. As algorithms synthesize elastography scores with serum markers, decision support tools flag progression that warrants specialist referral, reinforcing a tiered-care model. Vendors therefore prioritize cloud connectivity and automated reporting, adding software subscriptions to hardware revenue.

MASLD held 33.41% of liver disease diagnostics market share in 2025 and expands fastest at 7.52% CAGR, propelled by the global surge in obesity and type 2 diabetes. Cross-sectional screening reveals that 59% of diabetic patients harbor undiagnosed fatty liver, a prevalence that compels guidelines to recommend annual testing. Viral hepatitis remains a sizable niche in Asia-Pacific, sustaining demand for HBV DNA quantification and genotyping assays that inform antiviral therapy. Alcohol-related liver disease, while stable in incidence, still necessitates fibrosis monitoring because abstinence alone does not halt progression once cirrhosis develops. Auto-immune liver disease, though rare, commands premium pricing owing to complex serological panels.

Diagnostic complexity grows as etiologies overlap: a single patient may present with metabolic steatosis superimposed on chronic Hepatitis B and alcohol use. Multi-omics panels capable of parsing overlapping signatures therefore gain traction, and AI scoring engines distill disparate biomarkers into actionable risk grades. Liquid biopsy platforms enter early-cancer surveillance, showing 86% sensitivity at 88% specificity for stage I hepatocellular carcinoma, a performance level that edges out ultrasound screening. MASLD's chronic, progressive nature assures recurring testing every six to 12 months, underpinning sustained reagent demand.

Complete Report Scope:

• By Diagnosis Technique
  • Imaging Tests
    • Ultrasound
    • MRI & MRI-Elastography
    • CT & PET-CT
  • Liver Function Tests
  • Non-invasive Elastography Devices
  • Liver Biopsy
  • Endoscopy
  • Molecular & Serologic Tests
• By Disease Type
  • NAFLD / MASLD
  • Viral Hepatitis (HBV, HCV)
  • Alcohol-related Liver Disease
  • Auto-immune Liver Diseases
  • Liver Cancer & Cirrhosis
• By Technology Platform
  • Clinical Chemistry
  • Immunoassay
  • Molecular Diagnostics
  • Imaging Devices
  • Point-of-Care Biosensors
• By End User
  • Hospitals
  • Independent Clinical Laboratories
  • Academic & Research Institutes
  • Point-of-Care / Specialty Clinics
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 36.78% of liver disease diagnostics market share in 2025, buoyed by robust reimbursement and early adoption of breakthrough technologies. FDA fast-track pathways, such as the De Novo clearance for point-of-care Hepatitis C RNA testing, accelerate commercialization timelines. Medicare's 2025 laboratory fee schedule provides predictable payment for validated assays, fostering capital investment in new platforms. Strategic acquisitions-Quest Diagnostics' USD 1.0 billion purchase of LifeLabs-expand regional footprints and enhance test accessibility.

Asia-Pacific is poised to record a 9.18% CAGR through 2031, reflecting both the world's highest Hepatitis B prevalence and rapid metabolic-disease growth. Mainland China deploys nationwide MASLD screening pilots, while Japan reimburses the Enhanced Liver Fibrosis test, underscoring governmental commitment to early detection. India's blended public-private healthcare model spurs demand for low-cost point-of-care devices in rural areas, whereas Australia and South Korea adopt AI-integrated imaging platforms early thanks to advanced digital infrastructure. Regional disease burden-75% of chronic Hepatitis B patients reside in Asia-Pacific-creates sustained demand for quantitative viral assessment and fibrosis monitoring.

Europe maintains a solid second position, supported by coordinated policy initiatives such as the EASL-Lancet Commission on prevention and early diagnosis. Germany and the United Kingdom drive capital equipment uptake for MRI-elastography and AI image analysis, while France emphasizes cost-effectiveness studies that validate reimbursement decisions. Population screening pilots in Spain and Italy target MASLD, reflecting concern over rising obesity rates. Eastern European markets gradually modernize laboratory infrastructure through EU cohesion funds, while the Middle East and Africa represent nascent opportunities where private hospital chains import advanced modalities to meet affluent patient demand.

1. Abbott Laboratories
2. Roche
3. Siemens Healthineers
4. Thermo Fisher Scientific
5. Randox Laboratories
6. Boston Scientific
7. Laboratory Corporation of America (LabCorp)
8. bioMerieux
9. Quest Diagnostics
10. Mindray
11. Echosens
12. DiaSorin
13. Sysmex
14. QuidelOrtho
15. PerkinElmer (Revvity)
16. Canon
17. GE Healthcare
18. Koninklijke Philips
19. FUJIFILM
20. Meridian Bioscience

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Prevalence Of Liver Diseases Worldwide
  • 4.2.2 Rising Alcohol Consumption & Metabolic Risk Factors
  • 4.2.3 Uptake Of Non-Invasive Imaging
  • 4.2.4 Government Initiatives for Population Screening for Liver Diseases
  • 4.2.5 AI-Powered Multi-Omics Liquid Biopsy For Transplant Monitoring
  • 4.2.6 Expansion Of Point-of-Care Alt/Ast Nano-Biosensors
• 4.3 Market Restraints
  • 4.3.1 High Cost Of Comprehensive Diagnostic Work-Ups
  • 4.3.2 Limited Reimbursement For Novel Biomarker Panels
  • 4.3.3 Patient Aversion To Invasive Liver Biopsy Procedures
  • 4.3.4 Shortage Of Trained Hepatology Radiologists In LMICs
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technology Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size and Growth Forecasts (Value-USD)

• 5.1 By Diagnosis Technique
  • 5.1.1 Imaging Tests
    • 5.1.1.1 Ultrasound
    • 5.1.1.2 MRI & MRI-Elastography
    • 5.1.1.3 CT & PET-CT
  • 5.1.2 Liver Function Tests
  • 5.1.3 Non-invasive Elastography Devices
  • 5.1.4 Liver Biopsy
  • 5.1.5 Endoscopy
  • 5.1.6 Molecular & Serologic Tests
• 5.2 By Disease Type
  • 5.2.1 NAFLD / MASLD
  • 5.2.2 Viral Hepatitis (HBV, HCV)
  • 5.2.3 Alcohol-related Liver Disease
  • 5.2.4 Auto-immune Liver Diseases
  • 5.2.5 Liver Cancer & Cirrhosis
• 5.3 By Technology Platform
  • 5.3.1 Clinical Chemistry
  • 5.3.2 Immunoassay
  • 5.3.3 Molecular Diagnostics
  • 5.3.4 Imaging Devices
  • 5.3.5 Point-of-Care Biosensors
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Independent Clinical Laboratories
  • 5.4.3 Academic & Research Institutes
  • 5.4.4 Point-of-Care / Specialty Clinics
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
  • 6.3.1 Abbott
  • 6.3.2 F. Hoffmann-La Roche
  • 6.3.3 Siemens Healthineers
  • 6.3.4 Thermo Fisher Scientific
  • 6.3.5 Randox Laboratories
  • 6.3.6 Boston Scientific
  • 6.3.7 Laboratory Corporation of America (LabCorp)
  • 6.3.8 bioMerieux
  • 6.3.9 Quest Diagnostics
  • 6.3.10 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 6.3.11 Echosens
  • 6.3.12 DiaSorin
  • 6.3.13 Sysmex
  • 6.3.14 QuidelOrtho
  • 6.3.15 PerkinElmer (Revvity)
  • 6.3.16 Canon Medical Systems
  • 6.3.17 GE HealthCare
  • 6.3.18 Philips Healthcare
  • 6.3.19 Fujifilm Healthcare
  • 6.3.20 Meridian Bioscience

7 Market Opportunities and Future Outlook

• 7.1 White-Space and Unmet-Need Assessment